Company profile: MetrioPharm
1.1 - Company Overview
Company description
- Provider of clinical-stage pharmaceutical development for chronic inflammatory diseases including psoriasis, arthritis, and multiple sclerosis. Offers MP1032, an oral immune modulator that normalizes energy metabolism of inflammatory immune cells and reduces corticosteroid-associated side effects without immunosuppression, with Phase IIa efficacy in psoriasis and COVID-19 and preclinical efficacy in Rheumatoid Arthritis and Duchenne muscular dystrophy.
Products and services
- MP1032: Oral small-molecule immune modulator normalizing energy metabolism in inflammatory immune cells, reducing corticosteroid-associated side effects without immunosuppression, with Phase IIa efficacy in psoriasis/COVID-19 and preclinical activity in RA/DMD
- Chronic inflammatory–focused Drug Development: MetrioPharm architects clinical-stage pharmaceutical programs developing drugs for psoriasis, arthritis, and multiple sclerosis to make therapies more effective and more tolerable
- Disease-area–specific Scientific Advisory Board: A group of experts delivers guidance in immunology, pathology, inflammatory processes, and specific diseases such as Duchenne muscular dystrophy to steer development in chronic inflammatory indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to MetrioPharm
MedImmune
HQ: United States
Website
- Description: Provider of biologics research and development as the global biologics research and development arm of AstraZeneca, developing medicines for unmet medical needs worldwide and pioneering innovative research and exploring novel pathways across key therapeutic areas including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; and neuroscience.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MedImmune company profile →
Vaccinogen
HQ: United States
Website
- Description: Provider of vaccines and other immunotherapeutic products for cancers and infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaccinogen company profile →
Orega Biotech
HQ: France
Website
- Description: Provider of immunotherapeutic monoclonal antibodies for cancer, including IPH5201, a humanized CD39 blocking antibody that inhibits adenosine production and is in Phase 2 trials for non-small cell lung cancer, and a novel preclinical human-mouse cross-reactive blocking antibody that improves the efficacy of anti-PD-1 therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Orega Biotech company profile →
SuppreMol
HQ: Germany
Website
- Description: Provider of biotechnology therapies pioneering a novel approach to treat autoimmune diseases, aiming to cure these disorders rather than merely manage symptoms; privately held.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SuppreMol company profile →
Vyriad
HQ: United States
Website
- Description: Provider of clinical-stage oncolytic virotherapies and gene therapy platforms, including Voyager-V1 (VSV-based oncolytic virotherapy in trials for multiple cancers), Measles-NIS (oncolytic measles virus encoding NIS for precision targeting and monitoring), oncolytic virus platforms using VSV and measles, in vivo gene therapy vectors, and engineered lentiviral vectors; conducts phase 1/2 clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vyriad company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for MetrioPharm
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to MetrioPharm
2.2 - Growth funds investing in similar companies to MetrioPharm
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for MetrioPharm
4.2 - Public trading comparable groups for MetrioPharm
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →